Health Care & Life Sciences » Biotechnology | Aduro Biotech Inc.

Aduro Biotech Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
8,532.00
119,456.00
415,654.00
347,432.00
326,103.00
266,439
Total Accounts Receivable
357.00
3,153.00
4,846.00
1,138.00
18,484.00
12,037
Other Current Assets
467.00
2,612.00
4,004.00
6,194.00
5,544.00
4,500
Total Current Assets
9,356.00
125,221.00
424,504.00
354,764.00
350,131.00
282,976
Net Property, Plant & Equipment
399.00
1,053.00
3,986.00
26,384.00
31,085.00
29,157
Total Investments and Advances
-
-
15,391.00
14,942.00
24,082.00
11,902
Intangible Assets
-
-
37,869.00
35,485.00
39,830.00
33,469
Other Assets
125.00
188.00
75.00
717.00
-
-
Total Assets
9,880.00
126,462.00
481,825.00
438,611.00
445,128.00
357,504
ST Debt & Current Portion LT Debt
11,583.00
-
-
-
-
Accounts Payable
763.00
5,030.00
5,086.00
2,206.00
1,150.00
Other Current Liabilities
2,085.00
39,185.00
25,980.00
28,426.00
40,251.00
Total Current Liabilities
14,431.00
44,215.00
31,066.00
30,632.00
41,401.00
Long-Term Debt
1,478.00
100.00
-
-
-
Provision for Risks & Charges
-
-
3,750.00
4,032.00
-
Deferred Taxes
-
-
7,350.00
450.00
6,538.00
Other Liabilities
-
2,592.00
178,037.00
170,858.00
159,716.00
Total Liabilities
15,909.00
46,907.00
220,203.00
211,391.00
207,655.00
Common Equity (Total)
38,758.00
61,297.00
261,622.00
227,220.00
237,473.00
Total Shareholders' Equity
38,758.00
61,297.00
261,622.00
227,220.00
237,473.00
Total Equity
38,758.00
61,297.00
261,622.00
227,220.00
237,473.00
Liabilities & Shareholders' Equity
9,880.00
126,462.00
481,825.00
438,611.00
445,128.00
Non-Equity Reserves
32,729.00
140,852.00
-
-
-

About Aduro Biotech

View Profile
Address
740 Heinz Avenue
Berkeley California 94710
United States
Employees -
Website http://www.aduro.com
Updated 07/08/2019
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The firm's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies.